Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis
Authors
Keywords
chemotherapy, clinical trial, cost-effectiveness, drug therapy, economic evaluation, hormonal therapy, network meta-analysis, partitioned survival model, prostate cancer
Journal
VALUE IN HEALTH
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-12-02
DOI
10.1016/j.jval.2021.10.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
- (2021) Lin Wang et al. JAMA Oncology
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
- (2019) Neeraj Agarwal et al. LANCET ONCOLOGY
- Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer
- (2019) Chethan Ramamurthy et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
- (2018) Alicia K. Morgans et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
- (2018) Kim N Chi et al. LANCET ONCOLOGY
- Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures
- (2017) Kai Yeung et al. MEDICAL CARE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients
- (2015) Andrew J. Lloyd et al. VALUE IN HEALTH
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now